Medication:
ranitidine
zantac antihistamine
Breastfeeding:
Data taken from Medications and Mothers Milk (Hale 2017 online access).
Relative infant dose quoted as 2.53%–9.14%. The pharmacological data would suggest that this drug can readily permeate breastmilk and from the m/p ratio (1.9–6.7) would appear to concentrate in breastmilk. Additionally, plasma pro- tein binding data (15%) suggest that much of the drug is free to pass into breast- milk. It has, however, only limited bio-availability (50%).
However, a single case study (Kearns et al. 1985) showed that, following a 150-mg dose given to the mother twice a day for two days, an infant consuming 1 litre of breastmilk per day would ingest 2.6 mg in 24 hours. This can be com- pared with an unlicensed paediatric dose of 1 mg per kilogramme three times a day used for gastro-oesophageal reflux in infants from 1 month to 2 years (BNFC).
Although this drug appears to concentrate in breastmilk, using case report data and knowledge of pharmacokinetics we can deduce that it reaches levels that are sub-therapeutic and no paediatric concerns have been reported.
Breastfeeding:
Data taken from Medications and Mothers Milk (Hale 2017 online access).
Relative infant dose quoted as 2.53%–9.14%. The pharmacological data would suggest that this drug can readily permeate breastmilk and from the m/p ratio (1.9–6.7) would appear to concentrate in breastmilk. Additionally, plasma pro- tein binding data (15%) suggest that much of the drug is free to pass into breast- milk. It has, however, only limited bio-availability (50%).
However, a single case study (Kearns et al. 1985) showed that, following a 150-mg dose given to the mother twice a day for two days, an infant consuming 1 litre of breastmilk per day would ingest 2.6 mg in 24 hours. This can be com- pared with an unlicensed paediatric dose of 1 mg per kilogramme three times a day used for gastro-oesophageal reflux in infants from 1 month to 2 years (BNFC).
Although this drug appears to concentrate in breastmilk, using case report data and knowledge of pharmacokinetics we can deduce that it reaches levels that are sub-therapeutic and no paediatric concerns have been reported.